AstraZeneca FY2025 EPS Forecast Increased by Leerink Partnrs

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of AstraZeneca in a research report issued to clients and investors on Sunday, November 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of $4.70 per share for the year, up from their prior forecast of $4.58. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for AstraZeneca’s FY2026 earnings at $5.32 EPS and FY2027 earnings at $5.92 EPS.

Several other research firms have also commented on AZN. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, Jefferies Financial Group began coverage on shares of AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Price Performance

Shares of AZN opened at $89.09 on Tuesday. The company has a 50 day moving average price of $81.73 and a 200-day moving average price of $75.87. AstraZeneca has a fifty-two week low of $61.24 and a fifty-two week high of $89.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The stock has a market capitalization of $276.30 billion, a PE ratio of 33.49, a PEG ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. During the same period in the prior year, the company posted $2.08 earnings per share. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. SCS Capital Management LLC acquired a new position in AstraZeneca during the 1st quarter worth about $3,066,000. Robbins Farley acquired a new stake in AstraZeneca in the 2nd quarter valued at about $1,857,000. Jennison Associates LLC raised its stake in shares of AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after acquiring an additional 1,605,133 shares during the last quarter. Oliver Luxxe Assets LLC lifted its position in shares of AstraZeneca by 6.0% during the second quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock worth $5,472,000 after purchasing an additional 4,449 shares in the last quarter. Finally, Alhambra Investment Management LLC bought a new stake in shares of AstraZeneca during the second quarter valued at approximately $320,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.